Onkologie. 2016:10(6):263-269 [Urol. praxi. 2016;17(4):159-166]

Immunotherapy for prostate cancer

Michal Podrazil1,2, Radek Špíšek1,2, Jiřina Bartůňková1,2
1 Ústav imunologie UK 2. LF a FN v Motole, Praha
2 SOTIO a.s., Praha

Prostate cancer is one of the most common cancers in men. Advances in the field of molecular immunology are leading to a deeper understanding of the interactions between the immune system and cancer, allowing identification of new targets in the immune system and resulting in the development of new anticancer agents. Immunotherapy is emerging as another promising treatment modality in prostate cancer in addition to classic hormonal therapy, radiotherapy and chemotherapy. The aim of this review is to present an overview of current immunotherapeutic approaches, which are being clinically tested in the management of prostate cancer.

Keywords: prostate cancer, immune system, immunotherapy

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Podrazil M, Špíšek R, Bartůňková J. Immunotherapy for prostate cancer. Onkologie. 2016;10(6):263-269.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Antonarakis ES, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int, 2012; 109(1): 32-39. Go to original source... Go to PubMed...
    2. Heidenreich A, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol, 2011; 59(1): 61-71. Go to original source... Go to PubMed...
    3. Heidenreich A, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol, 2014; 65(2): 467-479. Go to original source... Go to PubMed...
    4. Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med, 2004; 351(15): 1502-1512. Go to original source... Go to PubMed...
    5. Sartor A. Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): a three-arm phase III study (FIRSTANA). J Clin Oncol 34, 2016; (suppl; abstr 5006). Go to original source...
    6. Beer TM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med, 2014; 371(5): 424-433. Go to original source... Go to PubMed...
    7. Ryan CJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 2015; 16(2): 152-160. Go to original source... Go to PubMed...
    8. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol, 2004; 22: 329-360. Go to original source... Go to PubMed...
    9. Schellhammer PF, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology, 2013; 81(6): 1297-1302. Go to original source... Go to PubMed...
    10. Dimonte G. A cell kinetics model for prostate cancer and its application to clinical data and individual patients. J Theor Biol, 2010; 264(2): 420-442. Go to original source... Go to PubMed...
    11. Kantoff PW, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 2010; 363(5): 411-422. Go to original source... Go to PubMed...
    12. Arlen PM, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res, 2006; 12(4): 1260-1269. Go to original source... Go to PubMed...
    13. Kantoff PW, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol, 2010; 28(7): 1099-1105. Go to original source... Go to PubMed...
    14. Rozkova D, et al. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clin Immunol, 2009; 131(1): 1-10. Go to original source... Go to PubMed...
    15. Podrazil M, et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget, 2015; 6(20): 18192-18205. Go to original source... Go to PubMed...
    16. Cordes LM, Gulley JL, Madan RA. The evolving role of immunotherapy in prostate cancer. Curr Opin Oncol, 2016; 28(3): 232-240. Go to original source... Go to PubMed...
    17. Kwon ED, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol, 2014; 15(7): 700-712. Go to original source... Go to PubMed...
    18. Fucikova J, et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer, 2014; 135(5): 1165-1177. Go to original source... Go to PubMed...
    19. Petrylak DP. A Phase 2 Study of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Following Abiraterone and/or Enzalutamide. J Clin Oncol 33, 2015; (suppl 7; abstr 144). Go to original source...
    20. Wolchok JD, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res, 2009; 15(23): 7412-7420. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.